Dr. Faisal Khan

Dr. Faisal Khan



Associate Professor

Cumming School of Medicine, Department of Pathology and Laboratory Medicine

Associate Professor

Cumming School of Medicine, Department of Pediatrics


Arnie Charbonneau Cancer Institute

Associate Member

The Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases

Child Health & Wellness Researcher

Alberta Children's Hospital Research Institute

Contact information

Web presence

Phone number

Office: 403.210.8652


Office: HMRB324

Preferred method of communication

Administrative Assistant

Cindy Miskolczi-McCallum
Email: cindy.miskolczimccal@ucalgary.ca

Telephone: 403.210.3935


Educational Background

B.S. Microbiology, Barkatullah University Bhopal, 1997

Doctor of Philosophy Biotechnology, Bundelkhand University, 2006

M.S. Biotechnology, Barkatullah University Bhopal, 1999


Dr. Khan is an Associate Professor in the Faculty of Medicine at University of Calgary and ACHF Chair of Pediatric Hematology. Dr. Khan has a cross appointment with Calgary Laboratory Services as an Associate Clinical Director of Tissue Typing and Molecular Haematology Laboratories; and as Director of Hematology Translational Lab.

Dr. Khan is a certified Diplomate of American Board of Histocompatibility and Immunogenetics (ABHI). Dr. Khan obtained his PhD in Human Molecular Genetics from SGPGIMS, Lucknow in India and pursued a postdoctoral research and clinical fellowships in Transplant Immunology and Immunogenetics at University of Calgary and Calgary Laboratory Services.


Areas of Research

Area of Focus
  • histocompatibility and immunogenetics
  • transplant immunology
  • NK cells
  • Killer Immunoglobulin-like Recpeto
Summary of Research

Four approaches of Precision Medicine in Hematological Malignancies:

Approach #1: Development of new molecular classification for diagnosis and risk assessment of different myeloid and lymphoid malignancies. We are currently using next generation sequencing based approach to identify and characterize driver somatic variant involved in the pathogenesis and prognosis of acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia and Non-Hodgkin’s lymphoma.

Approach #2: Improving immunogenetic selection of donors for Hematopoietic Cell Transplantation. We are studying two immunogenetic systems: Killer Immunoglobulin like receptors (KIRs) and Promoter gene variants of Cytokine genes to improve donor selection algorithm and thereby reduce the incidence of HCT complications like graft versus host disease (GVHD), relapse of malignancy and infectious complications like posttransplant lymphoproliferative disease (PTLD).

Approach #3: Molecular prediction of leukemia/lymphoma relapse. We are studying three models: posttransplant chimerism in CD34+ cells; somatic variant based measurable residual disease analyses and recovery of immunity related transcriptome after allogeneic HCT for an early and accurate prediction of relapse of underlying malignancy after HCT.

Approach #4: Cellular assessment of Immunotherapy. We are studying different immunotherapeutic responses: (1) CAR T cell functions against B-cell malignant targets; (2) NK cell mediated ADCC against malignant B cell target in response to Rituximab; (3) Virus-specific T cell function against CMV, EBV, VZV and BK-virus.

Participation in university strategic initiatives


  • award, American Society of Hematology Meeting. 2017
  • award, 2016
  • award, Alberta Children Hospital Foundation. 2015
  • Department of Pathology and Laboratory Medicine., 2015
  • award, 2014
  • award, 2013
  • award, 2012
  • award, 2011